- Home
- OMCL vs TVTX Comparison
OMCL vs TVTX Comparison
Compare OMCL & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMCL
- TVTX
- Stock Information
- Founded
- OMCL 1992
- TVTX 2008
- Country
- OMCL United States
- TVTX United States
- Employees
- OMCL N/A
- TVTX N/A
- Industry
- OMCL Computer Manufacturing
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- OMCL Technology
- TVTX Health Care
- Exchange
- OMCL Nasdaq
- TVTX Nasdaq
- Market Cap
- OMCL 1.5B
- TVTX 1.5B
- IPO Year
- OMCL 2001
- TVTX N/A
- Fundamental
- Price
- OMCL $30.83
- TVTX $17.28
- Analyst Decision
- OMCL Buy
- TVTX Strong Buy
- Analyst Count
- OMCL 7
- TVTX 16
- Target Price
- OMCL $46.71
- TVTX $33.40
- AVG Volume (30 Days)
- OMCL 588.7K
- TVTX 1.4M
- Earning Date
- OMCL 07-31-2025
- TVTX 08-06-2025
- Dividend Yield
- OMCL N/A
- TVTX N/A
- EPS Growth
- OMCL N/A
- TVTX N/A
- EPS
- OMCL 0.49
- TVTX N/A
- Revenue
- OMCL $1,149,529,000.00
- TVTX $333,865,000.00
- Revenue This Year
- OMCL $3.84
- TVTX $71.61
- Revenue Next Year
- OMCL $3.98
- TVTX $43.45
- P/E Ratio
- OMCL $62.55
- TVTX N/A
- Revenue Growth
- OMCL 6.39
- TVTX 87.94
- 52 Week Low
- OMCL $22.66
- TVTX $8.31
- 52 Week High
- OMCL $55.75
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- OMCL 59.87
- TVTX 64.04
- Support Level
- OMCL $30.32
- TVTX $15.60
- Resistance Level
- OMCL $31.64
- TVTX $17.46
- Average True Range (ATR)
- OMCL 1.20
- TVTX 0.81
- MACD
- OMCL 0.23
- TVTX 0.16
- Stochastic Oscillator
- OMCL 49.20
- TVTX 86.87
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.